TERN Terns Pharmaceuticals Inc
Price (delayed)
$2.49
Market cap
$217.37M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.12
Enterprise value
$57.28M
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver
Highlights
The company's EPS rose by 12% YoY and by 5% QoQ
TERN's equity is up by 35% YoY but it is down by 5% QoQ
Terns Pharmaceuticals's quick ratio has decreased by 30% from the previous quarter but it has increased by 3.8% YoY
Terns Pharmaceuticals's debt has soared by 123% YoY and by 3.2% from the previous quarter
Key stats
What are the main financial stats of TERN
Market
Valuations
Earnings
Shares outstanding
87.3M
Market cap
$217.37M
Enterprise value
$57.28M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.61
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$101.87M
Net income
-$88.85M
EBIT
-$88.59M
EBITDA
-$87.7M
Free cash flow
-$70.06M
Per share
Balance sheet
Liquidity
EPS
-$1.12
EPS diluted
-$1.12
Free cash flow per share
-$0.88
Book value per share
$4.07
Revenue per share
$0
TBVPS
$4.58
Total assets
$363.93M
Total liabilities
$18.06M
Debt
$1.35M
Equity
$345.87M
Working capital
$346.46M
Debt to equity
0
Current ratio
23.14
Quick ratio
22.89
Net debt/EBITDA
1.83
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-29.1%
Return on equity
-30.5%
Return on invested capital
-60.3%
Return on capital employed
-25.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TERN stock price
How has the Terns Pharmaceuticals stock price performed over time
Intraday
-2.73%
1 week
-19.68%
1 month
-32.52%
1 year
-62.5%
YTD
-55.05%
QTD
-9.78%
Financial performance
How have Terns Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$101.87M
Net income
-$88.85M
Gross margin
N/A
Net margin
N/A
Growth
What is Terns Pharmaceuticals's growth rate over time
Valuation
What is Terns Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.61
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 12% YoY and by 5% QoQ
The price to book (P/B) is 63% lower than the last 4 quarters average of 1.7 and 58% lower than the 5-year quarterly average of 1.5
TERN's equity is up by 35% YoY but it is down by 5% QoQ
Efficiency
How efficient is Terns Pharmaceuticals business performance
TERN's ROIC is down by 18% YoY
The company's return on assets rose by 9% YoY and by 7% QoQ
The return on equity is up by 9% year-on-year and by 7% since the previous quarter
Dividends
What is TERN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TERN.
Financial health
How did Terns Pharmaceuticals financials performed over time
TERN's total liabilities is up by 37% YoY and by 31% from the previous quarter
The total assets is up by 36% YoY but it is down by 3.8% from the previous quarter
Terns Pharmaceuticals's debt is 100% less than its equity
Terns Pharmaceuticals's debt has soared by 123% YoY and by 3.2% from the previous quarter
TERN's equity is up by 35% YoY but it is down by 5% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.